vs
Orthofix Medical Inc.（OFIX）与Victory Capital Holdings, Inc.（VCTR）财务数据对比。点击上方公司名可切换其他公司
Victory Capital Holdings, Inc.的季度营收约是Orthofix Medical Inc.的1.8倍（$388.0M vs $219.9M），Victory Capital Holdings, Inc.净利率更高（28.9% vs -1.0%，领先29.9%），Victory Capital Holdings, Inc.同比增速更快（76.7% vs 2.0%），过去两年Victory Capital Holdings, Inc.的营收复合增速更高（32.9% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Victory Capital Holdings是一家总部位于美国得克萨斯州圣安东尼奥的金融服务企业，核心业务为投资管理。除美国本土外，公司在伦敦、中国香港、新加坡三地均配备了专业投资团队，为全球客户提供资产管理相关服务。
OFIX vs VCTR — 直观对比
营收规模更大
VCTR
是对方的1.8倍
$219.9M
营收增速更快
VCTR
高出74.7%
2.0%
净利率更高
VCTR
高出29.9%
-1.0%
两年增速更快
VCTR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $388.0M |
| 净利润 | $-2.2M | $112.1M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 41.0% |
| 净利率 | -1.0% | 28.9% |
| 营收同比 | 2.0% | 76.7% |
| 净利润同比 | 92.4% | 80.8% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXVCTR
| Q1 26 | — | $388.0M | ||
| Q4 25 | $219.9M | $374.1M | ||
| Q3 25 | $205.6M | $361.2M | ||
| Q2 25 | $203.1M | $351.2M | ||
| Q1 25 | $193.6M | $219.6M | ||
| Q4 24 | $215.7M | $232.4M | ||
| Q3 24 | $196.6M | $225.6M | ||
| Q2 24 | $198.6M | $219.6M |
净利润OFIXVCTR
| Q1 26 | — | $112.1M | ||
| Q4 25 | $-2.2M | $112.8M | ||
| Q3 25 | $-22.8M | $96.5M | ||
| Q2 25 | $-14.1M | $58.7M | ||
| Q1 25 | $-53.1M | $62.0M | ||
| Q4 24 | $-29.1M | $76.9M | ||
| Q3 24 | $-27.4M | $82.0M | ||
| Q2 24 | $-33.4M | $74.3M |
毛利率OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXVCTR
| Q1 26 | — | 41.0% | ||
| Q4 25 | 0.2% | 40.9% | ||
| Q3 25 | -8.3% | 38.2% | ||
| Q2 25 | -7.9% | 26.8% | ||
| Q1 25 | -25.2% | 42.3% | ||
| Q4 24 | -5.3% | 48.1% | ||
| Q3 24 | -9.6% | 53.3% | ||
| Q2 24 | -12.5% | 50.4% |
净利率OFIXVCTR
| Q1 26 | — | 28.9% | ||
| Q4 25 | -1.0% | 30.2% | ||
| Q3 25 | -11.1% | 26.7% | ||
| Q2 25 | -6.9% | 16.7% | ||
| Q1 25 | -27.4% | 28.2% | ||
| Q4 24 | -13.5% | 33.1% | ||
| Q3 24 | -13.9% | 36.3% | ||
| Q2 24 | -16.8% | 33.8% |
每股收益（稀释后）OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | $-0.05 | $1.33 | ||
| Q3 25 | $-0.57 | $1.11 | ||
| Q2 25 | $-0.36 | $0.68 | ||
| Q1 25 | $-1.35 | $0.96 | ||
| Q4 24 | $-0.76 | $1.18 | ||
| Q3 24 | $-0.71 | $1.24 | ||
| Q2 24 | $-0.88 | $1.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $75.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $2.4B |
| 总资产 | $850.6M | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXVCTR
| Q1 26 | — | $75.8M | ||
| Q4 25 | $82.0M | $163.7M | ||
| Q3 25 | $62.9M | $115.7M | ||
| Q2 25 | $65.6M | $107.9M | ||
| Q1 25 | $58.0M | $175.6M | ||
| Q4 24 | $83.2M | $126.7M | ||
| Q3 24 | $30.1M | $188.2M | ||
| Q2 24 | $26.4M | $119.0M |
总债务OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | — | $970.0M | ||
| Q3 25 | $157.2M | $972.0M | ||
| Q2 25 | $157.0M | $965.7M | ||
| Q1 25 | $156.9M | $964.8M | ||
| Q4 24 | $157.0M | $963.9M | ||
| Q3 24 | $118.5M | $982.7M | ||
| Q2 24 | $118.0M | $981.7M |
股东权益OFIXVCTR
| Q1 26 | — | $2.4B | ||
| Q4 25 | $450.0M | $2.4B | ||
| Q3 25 | $442.5M | $2.4B | ||
| Q2 25 | $458.3M | $2.5B | ||
| Q1 25 | $458.3M | $1.1B | ||
| Q4 24 | $503.1M | $1.1B | ||
| Q3 24 | $525.9M | $1.2B | ||
| Q2 24 | $546.0M | $1.1B |
总资产OFIXVCTR
| Q1 26 | — | $4.1B | ||
| Q4 25 | $850.6M | $4.2B | ||
| Q3 25 | $832.6M | $4.2B | ||
| Q2 25 | $837.2M | $4.2B | ||
| Q1 25 | $823.1M | $2.6B | ||
| Q4 24 | $893.3M | $2.5B | ||
| Q3 24 | $867.9M | $2.6B | ||
| Q2 24 | $882.0M | $2.5B |
负债/权益比OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.40× | ||
| Q3 25 | 0.36× | 0.41× | ||
| Q2 25 | 0.34× | 0.39× | ||
| Q1 25 | 0.34× | 0.84× | ||
| Q4 24 | 0.31× | 0.86× | ||
| Q3 24 | 0.23× | 0.84× | ||
| Q2 24 | 0.22× | 0.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $145.1M | ||
| Q3 25 | $12.4M | $165.9M | ||
| Q2 25 | $11.6M | $-6.6M | ||
| Q1 25 | $-18.4M | $81.1M | ||
| Q4 24 | $23.7M | $91.8M | ||
| Q3 24 | $11.7M | $99.8M | ||
| Q2 24 | $9.0M | $79.7M |
自由现金流OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $144.5M | ||
| Q3 25 | $2.5M | $164.8M | ||
| Q2 25 | $4.5M | $-7.5M | ||
| Q1 25 | $-25.1M | $79.5M | ||
| Q4 24 | $15.2M | $91.7M | ||
| Q3 24 | $6.3M | $99.4M | ||
| Q2 24 | $-360.0K | $79.5M |
自由现金流率OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 38.6% | ||
| Q3 25 | 1.2% | 45.6% | ||
| Q2 25 | 2.2% | -2.1% | ||
| Q1 25 | -13.0% | 36.2% | ||
| Q4 24 | 7.0% | 39.4% | ||
| Q3 24 | 3.2% | 44.0% | ||
| Q2 24 | -0.2% | 36.2% |
资本支出强度OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.2% | ||
| Q3 25 | 4.8% | 0.3% | ||
| Q2 25 | 3.5% | 0.3% | ||
| Q1 25 | 3.5% | 0.7% | ||
| Q4 24 | 4.0% | 0.1% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 4.7% | 0.1% |
现金转化率OFIXVCTR
| Q1 26 | — | — | ||
| Q4 25 | — | 1.29× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.19× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 1.07× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
VCTR
| Investment management fees | $316.4M | 82% |
| Fund administration and distribution fees | $71.6M | 18% |
